JP7181442B1 - 環状ペプチド化合物を含む製剤及びその製造方法 - Google Patents

環状ペプチド化合物を含む製剤及びその製造方法 Download PDF

Info

Publication number
JP7181442B1
JP7181442B1 JP2022548967A JP2022548967A JP7181442B1 JP 7181442 B1 JP7181442 B1 JP 7181442B1 JP 2022548967 A JP2022548967 A JP 2022548967A JP 2022548967 A JP2022548967 A JP 2022548967A JP 7181442 B1 JP7181442 B1 JP 7181442B1
Authority
JP
Japan
Prior art keywords
composition
compound
weight
formula
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548967A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022234850A5 (https=
JPWO2022234850A1 (https=
Inventor
隆充 植戸
友香理 久保木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2022234850A1 publication Critical patent/JPWO2022234850A1/ja
Priority to JP2022184220A priority Critical patent/JP2023015334A/ja
Application granted granted Critical
Publication of JP7181442B1 publication Critical patent/JP7181442B1/ja
Publication of JPWO2022234850A5 publication Critical patent/JPWO2022234850A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022548967A 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法 Active JP7181442B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184220A JP2023015334A (ja) 2021-05-07 2022-11-17 環状ペプチド化合物を含む製剤及びその製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079015 2021-05-07
JP2021079015 2021-05-07
PCT/JP2022/019540 WO2022234850A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184220A Division JP2023015334A (ja) 2021-05-07 2022-11-17 環状ペプチド化合物を含む製剤及びその製造方法

Publications (3)

Publication Number Publication Date
JPWO2022234850A1 JPWO2022234850A1 (https=) 2022-11-10
JP7181442B1 true JP7181442B1 (ja) 2022-11-30
JPWO2022234850A5 JPWO2022234850A5 (https=) 2023-04-05

Family

ID=83932759

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548967A Active JP7181442B1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法
JP2022184220A Withdrawn JP2023015334A (ja) 2021-05-07 2022-11-17 環状ペプチド化合物を含む製剤及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184220A Withdrawn JP2023015334A (ja) 2021-05-07 2022-11-17 環状ペプチド化合物を含む製剤及びその製造方法

Country Status (12)

Country Link
US (1) US20240366711A1 (https=)
EP (1) EP4299069A4 (https=)
JP (2) JP7181442B1 (https=)
KR (2) KR20230169093A (https=)
CN (1) CN117241817A (https=)
AU (1) AU2022270498A1 (https=)
BR (1) BR112023019622A2 (https=)
CA (1) CA3219090A1 (https=)
IL (1) IL306018A (https=)
MX (1) MX2023013099A (https=)
TW (1) TW202308679A (https=)
WO (1) WO2022234850A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法
CA3256645A1 (en) 2022-05-06 2025-04-23 Chugai Seiyaku Kabushiki Kaisha CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS
EP4585605A1 (en) * 2022-10-20 2025-07-16 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
JPWO2024219480A1 (https=) * 2023-04-20 2024-10-24

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100132A1 (ja) * 2011-12-28 2013-07-04 中外製薬株式会社 ペプチド化合物の環化方法
JP6880352B1 (ja) * 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2501219A (en) * 2011-02-04 2013-10-16 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof
JP6239979B2 (ja) 2011-03-04 2017-11-29 ニューヨーク・ユニバーシティ Ｒａｓの調節因子としての水素結合代替大環状分子
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
WO2018031730A2 (en) 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
JP7232758B2 (ja) 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
TW202309065A (zh) * 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100132A1 (ja) * 2011-12-28 2013-07-04 中外製薬株式会社 ペプチド化合物の環化方法
JP6880352B1 (ja) * 2019-11-07 2021-06-02 中外製薬株式会社 Ｋｒａｓ阻害作用を有する環状ペプチド化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
日本薬剤学会年会講演要旨集, vol. 29, JPN6022037356, 2014, pages 193 - 20, ISSN: 0004869646 *
日本薬剤学会年会講演要旨集，Vol.29，2014年，p.193(P20-32)
薬剤学, vol. 70, JPN6022037355, 2010, pages 192 - 5, ISSN: 0004869645 *
薬剤学，Vol.70 Suppl.，2010年，p.192(P-5)

Also Published As

Publication number Publication date
KR20230020548A (ko) 2023-02-10
KR20230169093A (ko) 2023-12-15
WO2022234850A1 (ja) 2022-11-10
IL306018A (en) 2023-11-01
EP4299069A4 (en) 2025-03-05
CN117241817A (zh) 2023-12-15
US20240366711A1 (en) 2024-11-07
EP4299069A1 (en) 2024-01-03
JP2023015334A (ja) 2023-01-31
CA3219090A1 (en) 2022-11-10
BR112023019622A2 (pt) 2023-11-14
AU2022270498A1 (en) 2023-10-05
TW202308679A (zh) 2023-03-01
MX2023013099A (es) 2023-11-17
JPWO2022234850A1 (https=) 2022-11-10
KR102582225B1 (ko) 2023-09-22

Similar Documents

Publication Publication Date Title
JP7181442B1 (ja) 環状ペプチド化合物を含む製剤及びその製造方法
US8026271B2 (en) Formulations of indol-3-yl-2-oxoacetamide compounds
ES2929526T3 (es) Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
RS67259B1 (sr) Kompozicije koje aktiviraju piruvat kinazu r (pkr)
US10927142B2 (en) Salts and polymorphs of SCY-078
EP3996714A1 (en) Formulations of rbp4 inhibitors and methods of use
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
WO2015054793A1 (en) Salt and crystal forms of plk-4 inhibitor
CN114072144A (zh) 外用磷酸肌醇3-激酶抑制剂
EA049912B1 (ru) Препарат, содержащий циклическое пептидное соединение, и способы его приготовления
HK40096081A (zh) 包含环状胜肽化合物的制剂及其制备方法
KR20210009153A (ko) 자가나노유화 약물전달시스템을 이용한 타다라필의 경구용 고형제 조성물 및 이의 제조방법
WO2021055863A1 (en) Pyruvate kinase r (pkr) activating compositions
TWI921305B (zh) Rbp4抑制劑之調配物及使用方法
CN113372332B (zh) 一种奥希替尼新晶型
WO2025235577A1 (en) Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
WO2025240802A1 (en) Novel compositions, devices and methods
WO2019137027A1 (zh) Galunisertib的晶型及其制备方法和用途
HK40079381A (en) Novel salts and polymorphs of scy-078
CN117343073A (zh) 含噻吩并环类衍生物、其制备方法及其在医药上的应用
CN120965687A (zh) Sstr4激动剂类化合物的晶体形式及其制备方法和用途
WO2019105217A1 (zh) Galunisertib的晶型及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220812

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221117

R150 Certificate of patent or registration of utility model

Ref document number: 7181442

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150